Octet® BLI Kinetic Screening In Biosimilar Development Brochure | Sartorius

Accelerating Biosimilar Development Using Real-Time Label-Free Binding Assessment

Access the Brochure Now

Octet® BLI Kinetic Screening In Biosimilar Development

Last updated: December 2023

Overview

Biosimilar development is a rapidly growing field in the pharmaceutical industry. These regulated drug “reproductions” help to lower healthcare costs and increase access to vital medicines. However, the inherent complexity of producing a biologically active copy of a protein means that high similarity to the reference medicinal product is required.

This article discusses how a single analyte concentration can be used to accelerate biosimilar development when using an Octet® Bio-Layer Interferometry (BLI) Label-Free Detection Systems for biomolecular interactions analysis.


  • Document type: Brochure
  • Page count: 8
  • Read time: 14 minutes


Complete the Form to Access the Brochure

Key Takeaways

  • Biosimilars offer a lower cost alternative to branded biologics
  • Single analyte concentration screens can rapidly increase sample throughput against multiple targets
  • Octet® BLI systems accelerate biosimilar development with real-time molecular interaction data
  • Octet® BLI systems simplify sample analysis, reducing time and cost
  • High-throughput screening with Octet® BLI increases development efficiency
  • Octet® BLI technology streamlines drug development, benefiting healthcare and patients

This Resource is Designed for:

  • Analytical Lab Assistants
  • Engineers
  • Lab Researchers
  • Quality Control Scientists
  • Biosimilar Manufacturer
  • Pharmaceutical Manufacturers

Applications Supported:

  • Biopharmaceutical Quality Control (QC) Testing
  • Bioanalytical QC
  • Bio-Layer Interferometry (BLI) Label-Free Detection
  • Kinetic Screening
  • Biosimilar Development
  • Pharmaceutical Development
  • Biomolecular Interactions Analysis

Complete the Form to Contact an Expert